膀胱炎性肌纤维母细胞瘤的分子异质性及临床病理相关性:20例以FN1::ALK融合为主并发现新激酶重排的研究
该研究对20例膀胱炎性肌纤维母细胞瘤(IMT)进行免疫组化、FISH和靶向RNA测序,发现ALK阳性率90%、ALK重排87.5%、基因融合88.9%,以FN1::ALK为主(75%),并发现TFG::ROS1等新融合;尽管55%累及肌层,临床结局良好(90%无病生存)。
要点
- 膀胱IMT以FN1::ALK融合为主,ALK免疫组化阳性率90%。
- 黏液样形态与FN1::ALK强相关,少细胞纤维型富集非FN1融合。
- 尽管常累及肌层,总体预后良好,支持保守治疗。
核心结论
- 膀胱IMT以FN1::ALK融合为主,与假肉瘤样肌纤维母细胞增生共享相同断裂点,支持其为ALK驱动肿瘤的生物学连续谱。
- 分子谱扩展至非FN1及ROS1融合,建议结合组织学引导的分子检测识别激酶融合。
- 尽管常见肌层侵犯,临床行为惰性,支持保守管理。
研究设计与样本
- 整合临床病理与分子研究,纳入20例膀胱IMT。
- 采用免疫组化、FISH和靶向RNA测序进行分子表征。
- 平均年龄45岁,平均随访32.6个月。
主要发现
- 临床表现:血尿85%,膀胱镜见息肉样/结节状肿块;肌层侵犯55%,膀胱周围软组织延伸5%。
- 组织学:梭形细胞密集区75%、黏液样50%、少细胞纤维型20%,45%呈混合特征。
- 免疫组化:ALK阳性90%(18/20),其中弥漫胞质染色17/18;角蛋白阳性83.3%。
- 分子:FISH检测ALK重排87.5%(14/16),RNA测序基因融合88.9%(16/18),FN1::ALK占75%(12/16)。
- 罕见融合包括VCL::ALK、DCTN1::ALK、PPFIBP1::ALK及新发现的TFG::ROS1;黏液样形态与FN1::ALK相关87.5%(7/8),少细胞纤维型富集非FN1融合75%(3/4)。
关键数值与推荐
- ALK免疫组化阳性率90%(18/20),以弥漫胞质染色为主(17/18)。
- FISH检测ALK重排率87.5%(14/16),信号分离比例13%至42%。
- RNA测序基因融合率88.9%(16/18),FN1::ALK占75%(12/16)。
- FN1::ALK与黏液样形态相关87.5%(7/8),非FN1融合与少细胞纤维型相关75%(3/4)。
- 90%无病生存,平均随访32.6个月。
临床怎么用
- 对膀胱IMT应结合组织学特征(如黏液样或纤维型)引导分子检测。
- 免疫组化ALK可初筛,FISH和RNA测序用于确认融合类型。
- 识别激酶融合(包括非FN1和ROS1融合)有助于诊断和潜在靶向治疗。
- 肌层侵犯不改变保守治疗的总体策略。
局限性
- 样本量较小(20例),部分检测例数有限。
- 随访时间有限(平均32.6个月)。
- 回顾性设计,未提及前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammatory myofibroblastic tumors (IMTs) of the urinary bladder are rare mesenchymal neoplasms with an incompletely defined molecular spectrum. This integrated clinicopathologic and molecular study of 20 bladder IMTs utilized immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and targeted RNA sequencing to characterize their molecular drivers. Clinically, patients (mean age 45 y) presented with hematuria (85%) and cystoscopic polypoid/nodular masses; despite muscularis propria invovlement (55%) or perivesical soft tissue extension (5%), clinical outcomes were excellent (90% disease-free survival; mean follow-up 32.6 mo), with 2 recurrences managed by repeat resection. Histologically, the tumors exhibited mixed growth patterns: compact spindle cell (75%), myxoid (50%), and hypocellular fibrous (20%), with 45% showing combined features. IHC revealed ALK positivity in 90% (18/20) of cases, predominantly diffuse cytoplasmic staining (17/18), while keratins (AE1/AE3 and/or CAM5.2) were positive in 83.3%. Molecular analysis identified ALK rearrangements in 87.5% (14/16) of FISH-tested cases (signal separation: 13% to 42%) and gene fusions in 88.9% (16/18) of RNA-sequenced cases, with FN1::ALK being the predominant fusion (75%, 12/16). Rare fusions included VCL::ALK , DCTN1::ALK , PPFIBP1::ALK , and a novel TFG::ROS1 (confirmed by RT-PCR and Sanger sequencing). Distinct genotype-phenotype correlations emerged: myxoid morphology strongly associated with FN1::ALK (87.5%, 7/8), while hypocellular fibrous patterns enriched non- FN1 fusions (75%, 3/4). The predominance of FN1::ALK fusions, sharing identical breakpoints ( ALK exons 18 to 19) with pseudosarcomatous myofibroblastic proliferations of the urinary bladder, alongside expanded molecular diversity (non- FN1/ROS1 fusions), supports their classification as a biological continuum of ALK -driven bladder mesenchymal neoplasms. These findings broaden the molecular genetic spectrum of bladder IMTs and advocate for histology-guided molecular testing to identify kinase fusions, reinforcing conservative management for these typically indolent tumors.
引用
- Zhao M, Yang X, Zhang Z, et al. Molecular Heterogeneity and Clinicopathologic Correlations in Inflammatory Myofibroblastic Tumors of the Urinary Bladder: A Study of 20 Cases With Predominant FN1::ALK Fusions and Novel Kinase Rearrangements. Am J Surg Pathol. 2025. PMID: 41097820. doi:10.1097/PAS.0000000000002477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。